BACKGROUND & AIMS: Dysregulated glucose homeostasis and lipid accumulation characterize non-alcoholic fatty liver disease (NAFLD), but underlying mechanisms are obscure. We report here that Krüppel-like factor 6 (KLF6), a ubiquitous transcription factor that promotes adipocyte differentiation, also provokes the metabolic abnormalities of NAFLD by post-transcriptionally activating PPARα-signaling. METHODS: Mice with either hepatocyte-specific depletion of KLF6 ('ΔHepKlf6') or global KLF6 heterozygosity (Klf6+/-) were fed a high fat diet (HFD) or chow for 8 or 16 weeks. Glucose and insulin tolerance tests were performed to assess insulin sensitivity. Overexpression and knockdown of KLF6 in cultured cells enabled the elucidation of underlying mechanisms. In liver samples from a cohort of 28 NAFLD patients, the expression of KLF6-related target genes was quantified. RESULTS: Mice with global- or hepatocyte-depletion of KLF6 have reduced body fat content and improved glucose and insulin tolerance, and are protected from HFD-induced steatosis. In hepatocytes, KLF6 deficiency reduces PPARα-regulated genes (Trb3, Pepck) with diminished PPARα protein but no change in Pparα mRNA, which is explained by the discovery that KLF6 represses miRNA 10b, which leads to induction of PPARα. In NAFLD patients with advanced disease and inflammation, the expression of miRNA 10b is significantly downregulated, while PEPCK mRNA is upregulated; KLF6 mRNA expression also correlates with TRB3 as well as PEPCK gene expression. CONCLUSIONS: KLF6 increases PPARα activity, whereas KLF6 loss leads to PPARα repression and attenuation of lipid and glucose abnormalities associated with a high fat diet. The findings establish KLF6 as a novel regulator of hepatic glucose and lipid metabolism in fatty liver.
BACKGROUND & AIMS:Dysregulated glucose homeostasis and lipid accumulation characterize non-alcoholic fatty liver disease (NAFLD), but underlying mechanisms are obscure. We report here that Krüppel-like factor 6 (KLF6), a ubiquitous transcription factor that promotes adipocyte differentiation, also provokes the metabolic abnormalities of NAFLD by post-transcriptionally activating PPARα-signaling. METHODS:Mice with either hepatocyte-specific depletion of KLF6 ('ΔHepKlf6') or global KLF6 heterozygosity (Klf6+/-) were fed a high fat diet (HFD) or chow for 8 or 16 weeks. Glucose and insulin tolerance tests were performed to assess insulin sensitivity. Overexpression and knockdown of KLF6 in cultured cells enabled the elucidation of underlying mechanisms. In liver samples from a cohort of 28 NAFLD patients, the expression of KLF6-related target genes was quantified. RESULTS:Mice with global- or hepatocyte-depletion of KLF6 have reduced body fat content and improved glucose and insulin tolerance, and are protected from HFD-induced steatosis. In hepatocytes, KLF6 deficiency reduces PPARα-regulated genes (Trb3, Pepck) with diminished PPARα protein but no change in Pparα mRNA, which is explained by the discovery that KLF6 represses miRNA 10b, which leads to induction of PPARα. In NAFLD patients with advanced disease and inflammation, the expression of miRNA 10b is significantly downregulated, while PEPCK mRNA is upregulated; KLF6 mRNA expression also correlates with TRB3 as well as PEPCK gene expression. CONCLUSIONS:KLF6 increases PPARα activity, whereas KLF6 loss leads to PPARα repression and attenuation of lipid and glucose abnormalities associated with a high fat diet. The findings establish KLF6 as a novel regulator of hepatic glucose and lipid metabolism in fatty liver.
Authors: Lars P Bechmann; Rebekka A Hannivoort; Guido Gerken; Gökhan S Hotamisligil; Michael Trauner; Ali Canbay Journal: J Hepatol Date: 2011-12-13 Impact factor: 25.083
Authors: Diana Vetter; Michal Cohen-Naftaly; Augusto Villanueva; Youngmin A Lee; Peri Kocabayoglu; Rebekka Hannivoort; Goutham Narla; Josep M Llovet; Swan N Thung; Scott L Friedman Journal: Hepatology Date: 2012-08-27 Impact factor: 17.425
Authors: Lars P Bechmann; Robert K Gieseler; Jan-Peter Sowa; Alisan Kahraman; Jochen Erhard; Inga Wedemeyer; Barbara Emons; Christoph Jochum; Thorsten Feldkamp; Guido Gerken; Ali Canbay Journal: Liver Int Date: 2010-04-09 Impact factor: 5.828
Authors: Weier Qi; John Holian; Christina Y R Tan; Darren J Kelly; Xin-Ming Chen; Carol A Pollock Journal: Int J Biochem Cell Biol Date: 2010-11-23 Impact factor: 5.085
Authors: Lars P Bechmann; Amalia Gastaldelli; Diana Vetter; Gillian L Patman; Laura Pascoe; Rebekka A Hannivoort; Ursula E Lee; Isabel Fiel; Ursula Muñoz; Demetrio Ciociaro; Young-Min Lee; Emma Buzzigoli; Luca Miele; Kei Y Hui; Elisabetta Bugianesi; Alastair D Burt; Christopher P Day; Andrea Mari; Loranne Agius; Mark Walker; Scott L Friedman; Helen L Reeves Journal: Hepatology Date: 2012-03-01 Impact factor: 17.425
Authors: U E Lang; P Kocabayoglu; G Z Cheng; Z Ghiassi-Nejad; U Muñoz; D Vetter; D A Eckstein; R A Hannivoort; M J Walsh; S L Friedman Journal: Oncogene Date: 2012-10-22 Impact factor: 9.867
Authors: D Weismann; D M Erion; I Ignatova-Todorava; Y Nagai; R Stark; J J Hsiao; C Flannery; A L Birkenfeld; T May; M Kahn; D Zhang; X X Yu; S F Murray; S Bhanot; B P Monia; G W Cline; G I Shulman; V T Samuel Journal: Diabetologia Date: 2010-12-29 Impact factor: 10.122
Authors: Sylvia J Horne; Jessica M Vasquez; Yiqing Guo; Victoria Ly; Sian E Piret; Alexandra R Leonardo; Jason Ling; Monica P Revelo; Daniel Bogenhagen; Vincent W Yang; John C He; Sandeep K Mallipattu Journal: Diabetes Date: 2018-08-16 Impact factor: 9.461